With their improved bioavailability and a straightforward manufacturing process, innovative lipid formulations such as softgels offer an attractive alternative to common oral solid dosage (OSD) forms like tablets and capsules, helping to streamline drug development.
Poor aqueous solubility continues to present a significant obstacle in oral drug development, contributing to low bioavailability, inconsistent absorption and increased development risk. As more drug candidates enter pipelines with challenging physicochemical properties, formulation teams are under pressure to identify delivery approaches that can improve exposure while remaining scalable and commercially viable.
Lipid-based formulations have emerged as an effective strategy for addressing these challenges. By helping maintain active ingredients in a dissolved state and supporting enhanced absorption, they offer a route to improved oral bioavailability for poorly water-soluble compounds.
Among these approaches, softgels are gaining increasing attention. Combining the benefits of lipid-based delivery with a well-established dosage form, softgels can support formulation flexibility, stability, manufacturability and patient acceptability throughout the development lifecycle.
This article explores the scientific rationale behind lipid formulation development, examines why softgels are becoming a technology of choice for poorly soluble compounds, and highlights how formulation teams can use lipid-based systems to optimise drug performance from early development through to commercialisation.
Access this document to learn:
- Why poor bioavailability remains a major barrier in oral drug development
- How lipid-based systems can improve solubility and absorption
- The role of softgels in delivering lipid formulations effectively
- How in vitro lipolysis studies can help predict in vivo performance
- Key considerations for scaling lipid formulations from development to commercial manufacture
Register your details to read more.
Download Now
No comments yet